Equities analysts forecast that Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) will post ($0.69) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Rhythm Pharmaceuticals’ earnings, with estimates ranging from ($0.83) to ($0.54). Rhythm Pharmaceuticals posted earnings of ($0.60) per share during the same quarter last year, which suggests a negative year over year growth rate of 15%. The business is scheduled to issue its next quarterly earnings report on Monday, May 13th.
On average, analysts expect that Rhythm Pharmaceuticals will report full year earnings of ($3.01) per share for the current fiscal year, with EPS estimates ranging from ($4.04) to ($2.25). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.83) per share, with EPS estimates ranging from ($3.95) to ($1.63). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Rhythm Pharmaceuticals.
Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings data on Friday, March 8th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.17).
Shares of RYTM stock traded down $0.22 during trading hours on Monday, hitting $25.74. The company’s stock had a trading volume of 57,200 shares, compared to its average volume of 84,056. The company has a market capitalization of $912.57 million, a P/E ratio of -10.77 and a beta of 1.40. Rhythm Pharmaceuticals has a 12-month low of $21.44 and a 12-month high of $37.23.
In related news, CEO Keith Michael Gottesdiener sold 10,290 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.09, for a total value of $309,626.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders sold 65,637 shares of company stock valued at $1,971,840. Company insiders own 4.93% of the company’s stock.
Several institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC raised its position in Rhythm Pharmaceuticals by 4.0% during the fourth quarter. FMR LLC now owns 1,690,007 shares of the company’s stock worth $45,427,000 after acquiring an additional 65,213 shares during the period. BlackRock Inc. raised its position in Rhythm Pharmaceuticals by 36.2% during the fourth quarter. BlackRock Inc. now owns 1,554,706 shares of the company’s stock worth $41,790,000 after acquiring an additional 413,203 shares during the period. Vanguard Group Inc. raised its position in Rhythm Pharmaceuticals by 12.3% during the third quarter. Vanguard Group Inc. now owns 1,048,186 shares of the company’s stock worth $30,575,000 after acquiring an additional 115,177 shares during the period. Vanguard Group Inc raised its position in Rhythm Pharmaceuticals by 12.3% during the third quarter. Vanguard Group Inc now owns 1,048,186 shares of the company’s stock worth $30,575,000 after acquiring an additional 115,177 shares during the period. Finally, Federated Investors Inc. PA raised its position in Rhythm Pharmaceuticals by 216.2% during the third quarter. Federated Investors Inc. PA now owns 790,421 shares of the company’s stock worth $23,057,000 after acquiring an additional 540,421 shares during the period. Hedge funds and other institutional investors own 92.00% of the company’s stock.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders.
Recommended Story: Price-Sales Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.